[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-349254-105":59,"doc-detail-349254-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","epigenetic-control-of-telomeric-rna-maintains-heterochromatin-in-telomerase-driven-cancers-research-summary","Epigenetic control of telomeric RNA maintains heterochromatin in telomerase-driven cancers - Research summary","","Tumor heterogeneity creates major clinical obstacles, yet direct inhibition of telomerase (hTERT) has provided limited therapeutic benefit. To find hTERT-linked vulnerabilities, researchers used synthetic dosage lethality with genome-wide CRISPR/Cas9 and shRNA screens in multiple isogenic cell pairs. They prioritized and validated 100 candidates via arrayed in vitro and pooled in vivo CRISPR screens across diverse models and patient-derived organoids. FTSJ3 emerged as a key target, where its depletion selectively impairs hTERT-positive cancer viability by destabilizing TERRA and disrupting SUV39H1-dependent H3K9 trimethylation and HP1 assembly, triggering apoptosis and genome instability.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/epigenetic-control-of-telomeric-rna-maintains-heterochromatin-in-telomerase-driven-cancers-research-summary/349254/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/epigenetic-control-of-telomeric-rna-maintains-heterochromatin-in-telomerase-driven-cancers-research-summary/349254.png","ImageObject",300,407,{"name":92,"@type":93},"eBook King","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-06","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why is direct inhibition of hTERT considered insufficient?","Question",{"text":113,"@type":114},"Although reactivation of telomerase (hTERT) is a near-universal cancer hallmark, direct hTERT inhibition has shown limited therapeutic benefit, motivating alternative vulnerability-finding strategies.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were hTERT-specific genetic vulnerabilities identified?",{"text":118,"@type":114},"Researchers applied a synthetic dosage lethality strategy using genome-wide CRISPR/Cas9 and shRNA screens across isogenic cell pairs with different hTERT expression, followed by arrayed in vitro and pooled in vivo CRISPR validation.",{"name":120,"@type":111,"acceptedAnswer":121},"What role does FTSJ3 play in hTERT-positive cancers?",{"text":122,"@type":114},"FTSJ3 depletion selectively impairs hTERT-positive cancer cell viability. Mechanistically, FTSJ3 installs 2′-O-methylation on the telomeric RNA TERRA, supporting TERRA stability and enabling SUV39H1 recruitment, H3K9 trimethylation, HP1 assembly, and repressive telomeric chromatin.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},349254,1790173948,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":56,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962088006270,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","Signal Transduction [and Targeted Therapy](and Targeted Therapy www.nature.com/sigtrans)[ www.nature.com/sigtrans](and Targeted Therapy www.nature.com/sigtrans)  \nEpigenetic control of telomeric RNA maintains heterochromatin in telomerase-driven cancers  \nJared D. W. Price1, Frederick S. Vizeacoumar2, Omar Abuhussein 1,3, Vincent Maranda 1, Yue Zhang1, Hironori Adachi4, Kathryn Nguyen5, Liliia Kyrylenko 1, Aline Rangel-Pozzo6, He Dong 1, Lihui Gong1, Ashlyn Materi 1, Prachi Walke1,7, Ashtalakshmi Ganapathysamy1, Connor Denomy1,7, Tanya Freywald 1, Renuka Dahiya 2, Hussain Elhasasna3, Anjali Saxena 1, Jeff P. Vizeacoumar 1, Hardikkumar Patel1, Karthic Rajamanickam 1, Diego M. de Oliveira 5, Mary Lazell-Wright1, Alain Morejon Morales2, Aanchal Aggarwal1,8, Jia Lin Xu5, Nezeka Alli1, Erika P. Munhoz1, Peng Gao 9, Jayme Salsman10, Dinesh Kumar Dahiya2, Naga Suresh Kola11, Cristina Gonzalez-Lopez 1, Patricia Thibault 7, Michael Levin7, Graham Dellaire10, Nicholas Jette11, Gary Groot 12, Martin Köbel13, Cheng-Han Lee 14,  \nLaura Hopkins3, Anand Krishnan7, Shahid Ahmed1, Christopher Eskiw 15, Khaled H. Barakat16, Aneesh Thakur 11, Yuliang Wu8, Ronald A. DePinho 17, Sabine Mai6, Yi-Tao Yu4 ✉ , Judy M. Y. Wong5 ✉ , Andrew Freywald2 ✉ and Franco J. Vizeacoumar 1,18 ✉  \n\n| | Tumor heterogeneity presents a major clinical challenge. Reactivation of telomerase (hTERT) is a near-universal hallmark of cancer, yet direct inhibition of hTERT has shown limited therapeutic beneﬁt. To uncover tractable telomerase-related vulnerabilities, we applied a synthetic dosage lethality (SDL) strategy to identify genes required only when hTERT is overexpressed. We performed genome-wide CRISPR/Cas9 and shRNA screens across multiple isogenic cell line pairs differing in hTERT expression. From these datasets, 100 high-conﬁdence candidates were prioritized and validated using an arrayed in vitro CRISPR screen and a pooledin vivo CRISPR screen across diverse cancer models, non-malignant cells, and patient-derived organoids. Through this pipeline, weidentiﬁed FTSJ3, an RNA 2′-O-methyltransferase, as a top SDL target of hTERT. Depletion of FTSJ3 selectively impaired the viability of hTERT-positive cancer cells while sparing normal cells. Mechanistically, FTSJ3 installs 2′-O-methylation on the telomeric RNA TERRA, a modiﬁcation essential for TERRA stability and function. Loss of FTSJ3 destabilizes TERRA, disrupts recruitment of the histone methyltransferase SUV39H1, and diminishes H3K9 trimethylation and HP1 assembly at sub-telomeric regions. This breakdown of repressive telomeric chromatin leads to genome instability and apoptosis speciﬁcally in hTERT-positive cells. These ﬁndings highlight SDL as a powerful strategy for uncovering targetable vulnerabilities and establish FTSJ3 as a central regulator of heterochromatin stability in telomerase-active cancers. Targeting FTSJ3 enzymatic activity offers a promising therapeutic entry | |\n| --- | --- | --- |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  | |\n|  |  |  |\n| | point, acting upstream of TERRA to eliminate telomerase-driven malignancies selectively. | |\n|  | Signal Transduction and Targeted Therapy (2026)11:213 ; [https://doi.org/10.1038/s41392-026-02750-0](https://doi.org/10.1038/s41392-026-02750-0) |  |\n|  |  |  |\n\nINTRODUCTION  \nCancer heterogeneity presents a signiﬁcant medical challenge, requiring therapies tailored not only to individual patients but also to the unique cancer clones that exist within diverse microenvironmental contexts1. This complexity renders the development of effective treatments particularly difﬁcult, as variations in genetic proﬁles and microenvironmental interactions can inﬂuence therapy responses. Multiregion biopsy offers a powerful tool to address the complexity of cancer heterogeneity by providing a  \nmore detailed and accurate map of the tumor’s genetic and microenvironmental landscape. However, ","cbCait728HeZrC9Y","https://ap.wps.com/l/cbCait728HeZrC9Y","pdf",8130804,"English","# Introduction\n## Tumor heterogeneity and multiregion biopsy\n## Telomeres, telomerase, and hTERT dependence in cancer\n## Telomerase composition and rationale for target discovery","[{\"question\":\"Why is direct inhibition of hTERT considered insufficient?\",\"answer\":\"Although reactivation of telomerase (hTERT) is a near-universal cancer hallmark, direct hTERT inhibition has shown limited therapeutic benefit, motivating alternative vulnerability-finding strategies.\"},{\"question\":\"How were hTERT-specific genetic vulnerabilities identified?\",\"answer\":\"Researchers applied a synthetic dosage lethality strategy using genome-wide CRISPR/Cas9 and shRNA screens across isogenic cell pairs with different hTERT expression, followed by arrayed in vitro and pooled in vivo CRISPR validation.\"},{\"question\":\"What role does FTSJ3 play in hTERT-positive cancers?\",\"answer\":\"FTSJ3 depletion selectively impairs hTERT-positive cancer cell viability. Mechanistically, FTSJ3 installs 2′-O-methylation on the telomeric RNA TERRA, supporting TERRA stability and enabling SUV39H1 recruitment, H3K9 trimethylation, HP1 assembly, and repressive telomeric chromatin.\"}]","Epigenetic control of telomeric RNA maintains heterochromatin in telomerase-driven cancers - Research summary | PDF",1790082460,48,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d698e7738ccbfc5e9947c7b6d880e354.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/39030d85bf40feada3b4cbcce2c64511.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a7dbf2595f08966303f3f194dc66c1c6.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/31180902a433d192ed4e5b1c05e5335a.webp",980,1301]